newsfilter
← Earnings
Earnings Releases·

Mentari Therapeutics, Inc. — Nine Months Ended September 30, 2026 Earnings Summary

  • Financial Performance:

    • Reported a net loss of $62.996 million for the nine months ended September 30, 2026, compared to a net loss of $6.652 million for the period from inception (June 13, 2025) to September 30, 2025.
    • Total operating expenses for the nine months ended September 30, 2026, were $62.010 million, driven by Research and Development (R&D) expenses of $57.709 million and General and Administrative (G&A) expenses of $4.301 million.
    • R&D expenses increased significantly from $6.101 million in the prior period (inception to September 30, 2025) to $57.709 million in the current nine-month period.
    • Net loss per share (basic and diluted) was $(12.56) for the nine months ended September 30, 2026, compared to $(1.33) for the inception period.
    • Cash and cash equivalents stood at $45.791 million as of September 30, 2026, a decrease from $46.259 million as of December 31, 2025.
    • Accumulated deficit increased to $(82.429) million as of September 30, 2026, from $(19.433) million as of December 31, 2025.
    • Total liabilities increased to $78.608 million as of September 30, 2026, from $10.264 million as of December 31, 2025, primarily due to a $49.980 million note payable to a related party and $13.896 million in related-party accounts payable.
    • Net cash used in operating activities was $47.973 million for the nine months ended September 30, 2026.
    • Net cash provided by financing activities was $47.505 million for the nine months ended September 30, 2026, driven by proceeds from a related-party note payable.
    • Stock-based compensation expense totaled $1.852 million for the nine months ended September 30, 2026.
    • Interest expense was $2.223 million for the nine months ended September 30, 2026, compared to $0 in the prior period.
  • Business Segments and Product Lines:

    • The Company operates as a single reportable segment focused on the research and development of migraine prevention therapies.
    • R&D expenses were allocated across five programs:
      • MT-001 (anti-PACAP monoclonal antibody): $26.646 million for the nine months ended September 30, 2026.
      • MT-002 (anti-PACAP and anti-CGRP bispecific antibody): $17.018 million for the nine months ended September 30, 2026.
      • MT-003 (anti-CGRP half-life extended antibody): $1.401 million for the nine months ended September 30, 2026.
      • MT-004 and MT-005 (antibodies directed at novel, undisclosed targets): $6.341 million and $3.936 million, respectively, for the nine months ended September 30, 2026.
    • On July 1, 2026, the Company entered into a License Agreement with Paragon for MT-001 and MT-002, committing to $10.5 million in clinical development milestones and $10.0 million in regulatory milestones, plus tiered royalties.
    • On July 1, 2026, the Company amended the Paragon Option Agreement to add MT-003, with potential milestone payments of up to $12.0 million (clinical) and $10.0 million (regulatory).
    • On July 1, 2026, the Company entered into a separate Antibody Discovery and Option Agreement with Paragon Labs for MT-004 and MT-005, with potential milestone payments of up to $12.0 million (clinical) and $10.0 million (regulatory).
    • The Company reimbursed Paragon $0.1 million for pre-effective date development costs related to MT-003 and $2.5 million ($1.0 million for MT-004 and $1.5 million for MT-005) for pre-effective date costs related to MT-004 and MT-005 in July 2026.
  • Other Key Points:

    • On November 6, 2026, the Company completed a merger with InMed Pharmaceuticals Inc., resulting in InMed changing its name to "Mentari Therapeutics, Inc." and the combined entity being led by the pre-merger Mentari management team.
    • In connection with the merger, the Company completed a "Mentari Pre-Closing Financing" raising approximately $490.0 million in aggregate gross proceeds immediately prior to the merger closing.
    • The Pre-Closing Financing consisted of a First Pre-Closing Financing of approximately $290.0 million (including $52.7 million of principal and accrued interest from a Convertible Note) and a Second Pre-Closing Financing of approximately $200.0 million.
    • Investors purchased shares of common stock and pre-funded warrants at prices of $1.8928 and $2.8923 per share, respectively, across the two financing closings.
    • A one-for-ten reverse stock split of InMed's common stock was effected on November 4, 2026.
    • The Company holds a $50.0 million Convertible Note from Fairmount Fund II (a related party) accruing interest at 12.0% per annum, maturing June 30, 2028, which converts upon the occurrence of a "Next Equity Financing" or Corporate Transaction.
    • As of September 30, 2026, the Company had $1.180 million in additional paid-in capital and $1.062 million in related-party common stock warrant liability.
    • The Company has not generated any revenue from product sales or other sources since inception.
    • Management expects existing cash and proceeds from the November 6, 2026 merger and financing to fund operating plans for at least twelve months from the issuance date of the financial statements.
Company
MENTARI THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology